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Abstract
Sterol 27-hydroxylase has been suggested to be involved in an alternative pathway for the elimination of cholesterol from macrophages
and early atherosclerotic lesions. We have previously shown that human lung macrophages as well as monocyte-derived macrophages have a
relatively high activity of sterol 27-hydroxylase (CYP27). This enzyme converts intracellular cholesterol into 27-hydroxycholesterol and
cholestenoic acid that flux from cultured cells into the medium. It is shown here that human monocytes have very low CYP27 activity and
CYP27 mRNA levels. During differentiation into macrophages, both CYP27 activity and CYP27 mRNA levels increase markedly after 4
days of culture in serum-free medium. Addition of macrophage-colony stimulating factor had no significant effect on the induction and
addition of fetal calf serum had an inhibitory effect. Cholesterol synthesis was found to be a critical factor for the production of 27-
oxygenated products by the macrophages cultured in serum-free medium. The increased capacity of the differentiated cells to eliminate
intracellular cholesterol is of interest and supports the contention that CYP27 is an antiatherogenic factor.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Atherosclerosis is a complex process involving different
genetic and environmental factors that interact with each
other [1,2]. The pathogenesis involves three major stages
[3]. Early lesions are characterised by formation of fatty
streaks in the arterial wall. These lesions consist mainly of
lipid-laden cells (foam cells) that are found in the subendo-
thelial space [4,5]. These cells originate mainly from circu-
lating monocytes [6], as well as smooth muscle cells of the
vessel wall [7]. In the second stage, there is intimal
thickening and formation of fibrous plaques [8]. As the
lesions advance, these plaques acquire a large lipid core
with variable numbers of macrophage foam cells close to
the shoulder [9]. Finally, the complicated form of the lesion
develops with core rupture and ulceration, calcification and
thrombosis leading to occlusion of the vessel [8].
The early stage of fatty streak formation is generally
considered to be reversible and different types of cytokines
have been shown to affect and modulate this stage of the
disease [7,10,11]. One of the factors that have recently been
implicated in the pathogenesis of atherosclerosis is macro-
phage-colony stimulating factor (M-CSF) [12–15]. M-CSF
is a glycoprotein of 85 kDa that regulates the differentiation,
proliferation and survival of mononuclear phagocytes [16–
18]. In addition, it also functions as a growth factor for other
cells such as bone osteoclasts, trophoblasts and smooth
muscle cells [19]. Besides its function as a growth factor,
it acts as a chemotactic agent for monocytes and can
regulate the function of mature monocytes and macrophages
[20–23]. All these different actions are mediated through
specific cell surface receptors encoded by the protoonco-
gene c-fms [24].
Recently, we have described a new oxidative mechanism
for elimination of cholesterol from human macrophages. In
this mechanism, cholesterol is converted to 27-hydroxycho-
lesterol (27-OH) and 3h-hydroxy-5-cholestenoic acid (CA)
by the sterol 27-hydroxylase. These metabolites are more
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polar and can be excreted more rapidly from the cells than
cholesterol [25]. The factors that influence this elimination
have been studied in detail [26]. The 27-oxygenated prod-
ucts are transported in the circulation to the liver where they
are taken up, converted into bile acids and finally excreted
in the bile [27,28]. In cultured human alveolar macrophages,
up to 40% of intracellular cholesterol could be removed by
this mechanism [28]. It has also been shown that about 5%
of the total bile produced per day is formed by this process
[28]. It is evident that this oxidative mechanism is of
importance in humans and constitutes a potential site for
manipulation to eliminate excess cholesterol from the cells.
Hence, it may retard the formation of foam cells in the
vascular wall and ultimately protect against the development
of atherosclerosis.
In the present study, we investigated the expression of the
sterol 27-hydroxylase enzyme and the effect of M-CSF on
this expression during differentiation of monocytes into
macrophages in vitro.
2. Materials and methods
2.1. Materials
M-CSF, fetal calf serum (FCS), mevalonic acid and
simvastatin were obtained from Sigma Chemical Com-
pany (St. Louis, MO); macrophage serum-free medium
(SFM) was purchased from Life Technologies Inc.; and
Ficoll-Paquek from Pharmacia Corp. All other reagents
and chemicals were high-purity standard commercial
products. Deuterium-labelled 27-OH and unlabelled 3h-
hydroxy-5-norcholestenoic acid were synthesized as
described previously [25]. Ultraspec reagent for total
RNA isolation was purchased from Nordic Biosite.
RPAIIIk kit and pTRI-h-actin-Human were purchased
from Ambion and Nick columns were obtained from
Amersham-Pharmacia.
The manufacturer does not provide the exact composition
of macrophage serum-free medium. Following a check for
the components that are of relevance to this study, it was
found that the medium contains no lipoproteins, small
amount of cholesterol (1 Ag/ml) and small amounts of
albumin (3 g/l).
2.2. Culturing of monocyte-derived macrophages and
isolation of total RNA
Monocytes were isolated from human buffy coats
obtained from a Swedish blood bank. Mononuclear cells
were isolated by centrifugation in Ficoll-Paquek, washed
and suspended in minimum essential medium supple-
mented with benzylpenicillin (400 U/ml) and streptomycin
(0.2 mg/ml) for at least 3 h at 37 jC at a concentration of
4 to 5 106 in 10 ml dishes. The non-adherent lympho-
cytes were removed and the adherent monocytes (approx-
imately 1 to 2 106 per dish) were incubated for 8 days in
serum-free medium (SFM) with or without M-CSF (50 ng/
ml) to promote differentiation into macrophages. The
medium was changed every 48 h, but in some experi-
ments, at other intervals. Medium removed from the dishes
was stored at  20 jC until analysis of 27-oxygenated
products. Two milliliters of Ultraspec was added to each
dish to remove the adherent cells. The cells were then
harvested, homogenised and stored at  70 jC until
isolation of total RNA and quantification using RNA
protection assay.
In some of the experiments, the monocyte-derived mac-
rophages were exposed to 20% FCS for 24 h to study the
effect of cholesterol loading on CYP27. Simvastatin (2 AM)
and mevalonate (200 AM) were added to monocyte-derived
macrophages for 24 h to investigate the source of choles-
terol for CYP27 during differentiation.
2.3. Measurement of 27-oxygenated steroids in culture
media by combined gas chromatography–mass spectrom-
etry (GC-MS)
The measurement of 27-oxygenated steroids was car-
ried out as described previously [28]. Two hundred
nanograms of 3h-hydroxy-5-norcholestenoic acid and
100 ng of [2H5]-27-hydroxycholesterol were added to
10 ml of cell culture medium. The medium was acidified
with hydrochloric acid and extracted with 20 ml of
diethyl ether. The ether phase was washed with water
until neutral and the solvent was removed under reduced
pressure. The residue was dissolved in 0.5 ml of chloro-
form and fractionated on a Bond-Elut NH2 cartridge. The
neutral lipid fraction, containing 27-OH, was collected
using chloroform/isopropanol (2:1) while the fatty acid
fraction containing CA was collected using 2% acetic
acid in ether. The fractions were dried under a stream of
argon. The fatty acid fraction was methylated with diazo-
methane and both fractions were converted into trime-
thylsilyl ethers.
A Hewlett-Packard 5890 GC coupled to a Hewlett-
Packard 5970 MSD mass spectrometer was used for the
analysis. [2H5]-27-hydroxycholesterol was used as an
internal standard for 27-OH, and 3h-hydroxy-5-norcho-
lestenoic acid was used as the internal standard for CA
[28].
2.4. Determination of protein content using spectropho-
tometry
The protein content in each sample was determined to
correct for differences in cell number. Chloroform (0.2 ml)
was added to 1 ml Ultraspec cell suspension and centrifuged
at 12000 rpm for 15 min. The protein phase was removed,
dried under a nitrogen stream, resuspended in 0.01 M
phosphate-buffer saline (pH 7.4) and protein was measured
using the Lowry method [29].
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2.5. Quantitation of CYP27 mRNA by ribonuclease
protection assay
Ribonuclease protection assays were performed using the
RPAIIIk kit according to the manufacturer’s instructions
[30]. In brief, RNA-probes for CYP27 (297 bp) and h-actin
(245 bp) were labelled with 32P-dUTP using T3 polymerase
and purified on NICK-columns. Total RNA and probes were
coprecipitated and dissolved in hybridization buffer. The
samples were allowed to hybridize with the probes at 46 jC
overnight. Following RNase treatment, the samples were
precipitated and redissolved in loading buffer. The protected
fragments (CYP27 297 bp, h-actin 245 bp) were separated
using a denaturing 5% polyacrylamide urea gel. These
fragments were detected and quantified using a Fujifilm
BAS 1800 phosphoimager.
2.6. Northern blot analysis
cDNA probes for CYP27 and ubiquitin were labelled
with a-32P dCTP (NEN Life Science Products, Belgium)
by random priming (Oligo-labelling kit, Amersham Phar-
macia Biotech). RNA filters were prehybridized for 1 h in a
solution containing 50 mM PIPES, 100 mM NaCl, 50 mM
sodium dihydrogen phosphate, 1 mM EDTA and 5% SDS
at pH 6.8, together with 100 Ag salmon sperm DNA
(Sigma) at 65 jC. Following prehybridization, the filters
were further hybridized overnight at 65 jC with the
relevant a-32P-labelled probe. Following hybridization,
the filters were initially washed at 65 jC in 1 SSC–5%
SDS and further washed in decreasing concentrations of
SSC–SDS solutions. Bands were visualised by exposure to
X-ray film (CEA RP medical X-ray screen film). Filters
were stripped in boiling 0.5% SDS solution and reprobed
as required.
2.7. Measurement of cholesterol in culture medium and in
cells by combined GC-MS
Measurement of cholesterol in the cell culture medium
was carried out by addition of 6 ml Folch (chloroform/
methanol 2:1 v/v) to 1 ml cell medium and 2 Ag [2H6]-
cholesterol as internal standard. The chloroform (lower)
fraction was collected and dried under a stream of argon
and converted to trimethylsilyl ethers and then analysed by
GC-MS.
To assay total cholesterol content in cells, Folch and cell
suspension was mixed and internal standard added in the
same proportions as above. After drying the chloroform
phase, the samples were subjected to hydrolysis by adding 1
ml ethanol and 0.25 ml KOH (33%) and stirring for 1 h at
room temperature. Two milliliters of chloroform and 1 ml
NaCl (0.9%) were added and the solution was mixed. The
chloroform phase was collected and dried under a stream of
argon and converted to trimethylsilyl ethers and analysed by
GC-MS.
3. Results and discussion
In a pilot experiment, monocytes were incubated in
serum-free medium in the presence of M-CSF for 7 days.
Northern blot analysis was used to detect CYP27 mRNA,
with ubiquitin as a control probe (Fig. 1). This experiment
showed that up to day 4 of differentiation, monocytes
expressed very low levels of sterol CYP27 mRNA. How-
ever at day 4 of differentiation, there was a marked increase
in CYP27 mRNA, which was maximal at day 6. In a
subsequent experiment, monocytes were cultured in SFM
with or without added M-CSF, and the ratio between CYP27
and h-actin mRNA levels were quantified by RNA protec-
tion assay (Fig. 2). There was also a marked increase in
sterol 27-hydroxylase mRNA levels at day 4 with a ten-
dency to plateau after day 5. The presence of M-CSF had no
significant effect on the expression of sterol 27-hydroxylase.
Fig. 3 shows the efflux of the two 27-oxygenated products,
27-OH and CA from the incubated cells into the medium
from the same experiment shown in Fig. 2. The flux of the
two metabolites increased in parallel with the increase in
mRNA levels during the first 5 days. During days 5–8, the
increase in flux was more marked than the increase in
mRNA levels. After about 1 week, the flux of the measured
oxysterols into the medium was about 10–20 times higher
than at day 1.
It is evident from the above results that exogenous M-
CSF is not a necessary factor for induction of CYP27. In
some experiments with M-CSF, a slightly higher cell count
was detected in the dishes containing M-CSF. This also
resulted in a comparably higher yield of 27-oxygenated
products in the medium. Differences in the protein contents
of the medium were corrected for in experiments where cell
number differed between M-CSF-containing dishes and
controls.
M-CSF has been shown to regulate and modify different
functions of monocytes and macrophage [21,22,29] affect-
ing both accumulation and efflux of cholesterol from the
cells. In addition, M-CSF has a cholesterol-lowering effect
in plasma [19,31]. However, independent animal experi-
Fig. 1. CYP27 is induced during differentiation of human monocytes into
macrophages. Northern blot showing mRNA levels of CYP27 and
ubiquitin. In this experiment, monocytes were cultured in serum-free
medium with addition of M-CSF (50 ng/ml). Samples taken at days 0, 1, 2,
3, 4, 5, 6 and 7 in the differentiation process.
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ments showed contrasting effects of M-CSF on the athero-
sclerotic process [18,32,33]. Our results here do not support
a direct effect of M-CSF on CYP27 that could lead to
enhanced efflux of cholesterol from macrophages. However,
in view of the complex process of atherosclerosis and the
wide influence of M-CSF on cholesterol metabolism in
monocytes and macrophages (see above), we cannot
exclude an effect on CYP27 that could be balanced by
modifications in other cholesterol pathways.
The differentiation of monocytes into macrophages in
serum-free medium was carried out using blood from differ-
ent donors to test the reproducibility of the differentiation
process. It is clear from Fig. 4 that there is a marked increase
in the products (CA+ 27-OH) in the medium during differ-
entiation from day 5. The increase in the products is due to
the induction of CYP27 mRNA in the cells as concluded
from Fig. 5. It is interesting to note in Fig. 4 that the ratio of
CA to 27-OH increases as the total amounts of the two
products increase. It has previously been reported that the
total production of 27-OH and CA as well as the ratio
between them in a given tissue depends on the level of
expression of CYP27 [26]. With increasing levels of the
CYP27 enzyme, more CA will be produced in relation to
27-OH [34]. When the total amount of 27-OH and CA in
Fig. 4 was plotted against the ratio between them, a good
correlation was obtained (Fig. 6), further confirming that the
Fig. 3. The efflux of 27-OH and CA from human monocytes during differentiation into macrophages. Total amount of 27-OH and CA (ng/106) cells in the
culture medium at days 1, 2, 3, 4, 5, 8 and 9 from M-CSF-induced cells and control cells. The graph represents meanF S.E. of five different experiments.
Fig. 2. CYP27 mRNA/h-actin mRNA during differentiation of monocytes into macrophages in serum-free medium. CYP27 mRNA and h-actin mRNA levels
were measured using RNase protection assay and expressed as a ratio CYP27/h-actin from M-CSF-induced cells and control cells. Samples taken at days 1, 2,
3, 4, 5 and 8 in the differentiation process. The graph represents the mean and individual values of mRNA from two dishes. Day 5 in the M-CSF curve was not
included due to a technical problem.
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increase in these 27-oxygenated products is due to the
increased expression of CYP27 in the cells.
It has previously been shown that CYP27 can act on
oxysterols such as 7-ketocholesterol to enhance their elim-
ination from cultured macrophages [35]. In addition, it has
been reported that a reconstituted system of recombinant
CYP27 can further hydroxylate CA in the steroid nucleus
[34]. However, we did not find any metabolites in the
medium other than 27-OH and CA when alveolar or mono-
cyte-derived macrophages were loaded with 14C-cholesterol
[26]. To study the relative contribution of the sterol 27-
hydroxylase mechanism for cholesterol removal during
differentiation of monocytes to macrophages, we measured
the intracellular content of cholesterol and 27-oxygenated
products in addition to the measurements made in the
medium of the experiments in Fig. 4. Monocytes were
found to have a relatively constant level of cholesterol, both
intracellularly (2 Ag/mg protein) and in the medium (0.4 Ag/
ml) during differentiation. Insignificant amounts of 27-OH
and CA were found intracellularly during differentiation
(results not shown). It appears from the above results that
the monocytes are in a state of cholesterol balance during
the differentiation in the albumin-containing serum-free
medium. There are two possible sources for the cholesterol
available as a substrate for CYP27: exogenous from the
medium or de novo synthesized. The low amount of
Fig. 5. Ratio between CYP27 mRNA and h-actin mRNA from monocytes during differentiation. The ratio of CYP27 mRNA to h-actin in human monocytes
during their differentiation into macrophages in vitro. Cells used for preparation of mRNA are the same as in Fig. 4. Student unpaired t-test was used to
calculate the P-value with the mRNA ratio from each day compared to the first day. In the diagram, each day is represented as the mean value of three to five
different experiments with S.E. indicated. *=P< 0.05.
 
Fig. 4. Production of 27-OH and CA in the medium during differentiation of monocytes into macrophages. 27-OH and CA (ng/106 cells) produced during
differentiation of human monocytes into macrophages in serum-free medium for 7 days. All points on the graph represent the mean value of four
experimentsF S.E. Student unpaired t-test was used to calculate the P-value, with the amount of products from each day compared to the first day. *=P < 0.05.
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cholesterol in the medium (1 Ag/ml) is unlikely to be the
major source of cholesterol. If endogenous cholesterol is the
main source, inhibition of its synthesis would be expected to
reduce production of 27-oxygenated products by the cells.
Addition of simvastatin (a HMG CoA reductase inhibitor)
markedly abolished the production of 27-oxygenated metab-
olites in the medium. Most of this inhibition could be
reversed by addition of mevalonic acid in addition to
simvastatin (Table 1). It is evident that CYP27 is mainly
utilizing endogenously produced cholesterol as a substrate
when monocytes are cultured in serum-free medium.
Because there is a marked induction of CYP27 in fully
differentiated macrophages, it was interesting to study how
these cells would deal with excess cholesterol. We differ-
entiated the monocytes into macrophages during 8 days in
serum-free medium. At day 8, the macrophages were
cultured in the presence or absence of FCS (20%) for 24
h. As shown in Table 2, presence of FCS led to a marked
reduction (about 50%) in the flux of 27-oxygenated prod-
ucts into the medium when compared to the control. How-
ever, the presence or absence of FCS had no effect on
CYP27 mRNA levels (results not shown). Considering the
fact that FCS contains lipoprotein cholesterol that may
function as a substrate for the sterol 27-hydroxylase, addi-
tion of FCS would be expected to give an increased flux of
27-oxygenated products. The presence of FCS also provides
acceptors for cholesterol molecules that may enhance
removal of cholesterol by the reverse cholesterol mechanism
[36]. In support of this, it has been shown that at least under
some experimental conditions, there is an inverse relation-
ship between sterol 27-hydroxylase-mediated flux of 27-
oxygenated metabolites and Apo-A1/phospholipid-mediated
efflux of cholesterol from cholesterol-loaded macrophages
[37]. In addition to this, the uptake of cholesterol will lead to
feedback inhibition of de novo synthesis of cholesterol and
down-regulation of the LDL receptor, thus decreasing the
newly synthesized substrate available for the CYP27
enzyme. This may in part explain the inhibitory effect
obtained by addition of FCS. The possibility cannot be
completely excluded that a small part of the decrease in 27-
hydroxylated sterol metabolites in the media may be due to
a reduced mitochondrial function. In theory, simvastatin
could possibly inhibit mitochondrial function through inhib-
ition of products other than cholesterol that use mevalonate
as precursor, such as ubiquinone (coenzyme Q).
The use of serum-free medium for studies on the differ-
entiation of monocytes to macrophages in vitro has the
advantage of having the same composition each time we use
it and so avoiding batch-to-batch variations which may arise
when serum is used [38]. In this regard, it has been shown
that monocytes can be differentiated into mature macro-
phages that display marked heterogeneity of phenotype in
Table 1
The effect of simvastatin and simvastatin +mevalonate on production of 27-
OH and CA by monocyte-derived macrophages cultured in serum-free
medium
27-OH
(ng/106 cells)
CA
(ng/106 cells)
Total
(ng/106 cells)
Control 400
(300, 500)
800
(650, 950)
1200
(950, 1450)
Simvastatin
(2 AM)
90
(70, 110)
80
(60, 100)
170
(130, 210)
Simvastatin
(2 AM)+Mevalonate
(200 AM)
160
(100, 220)
510
(400, 820)
770
(500, 1040)
Results represent the mean of two independent experiments.
Fig. 6. Ratio of CA/27-OH in relation to total amount produced. The ratio between CA and 27-OH is plotted against the sum of these two products from each
day during differentiation using the same data as shown in Fig. 4.
Table 2
Production of 27-OH and CA measured in the medium from monocyte-
derived macrophages cultured for 24 h in the presence or absence of 20%
FCS
27-OH
(ng/106 cells)
CA
(ng/106 cells)
Total
(ng/106 cells )
Control 400
(390, 420)
620
(530, 700)
1020
(850, 1090)
FCS (20%) 252
(204, 300)
370
(290, 450)
622
(494, 750)
Data represent the mean of two independent experiments. FCS did not
contain 27-OH or CA and cholesterol concentration in the medium was
0.75 mg/ml.
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different tissues depending on the conditions of differentia-
tion [38,39]. In addition, the possibility must be considered
that serum is an unphysiological medium that may contain
factors liberated in the coagulation process that may affect
CYP27 induction and/or activity. Experiments designed to
study this possibility are in progress. In humans, the
composition of the interstitial compartment varies in differ-
ent tissues, and even within the same tissue from one site to
another [40]. In this regard, the subendothelial compartment
in the vascular wall is of particular interest because this is
where the monocytes may differentiate into macrophages
and be converted into foam cells [1,4]. It has been shown
that the concentration of LDL in the inner intima, adjacent
to the endothelium, is about twice the plasma concentration,
whereas the albumin concentration is only one quarter of its
plasma concentration [41]. It is evident that induction of the
CYP27 enzyme at the site of increased concentration of
LDL may be advantageous and may retard the formation of
foam cells and development of atherosclerotic lesions.
In conclusion, the induction of CYP27 during differ-
entiation of monocytes into macrophages is of interest in
relation to the suggested anti-atherogenic role of the enzyme
[42]. The presence of CYP27 enzyme in the macrophages
may thus be a preventive factor in connection with con-
version of the macrophages into foam cells. If so, it would
be an advantage to further increase the induction of the
enzyme during the differentiation process. Experiments
designed to find conditions and factors for this are in
progress.
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